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Aortic regurgitation in athletes: Pieces
of the puzzle we have so far omitted
E Cavarretta1,2, G Frati1,3, L Sciarra4 and M Peruzzi1,2
The prevalence of valvular heart disease (VHD) rises
with age, reaching 11.7% in individuals older than
75 years.1 In young individuals, VHD is usually related
to the presence of a congenital valve abnormality, as
bicuspid aortic valve (BAV) or mitral valve prolapse.
This is also the case for athletes, where in the presence
of these abnormalities few restrictions exist in eligibility
for competitive sports participation, even if a strict
follow-up would be desirable. BAV is the most
common congenital valve abnormality (1%) found in
the general population and in athletes. BAV is more
prevalent in males and it can lead to aortic regurgita-
tion (AR), aortic stenosis and/or aortic root dilation.
At present, no definitive studies have proved that inten-
sive sports participation could worsen the progression
of BAV and limited data are available on athletes.
Longitudinal data from a population of 210 athletes
with BAV2 showed that there is a progressive signifi-
cant enlargement of the left ventricle (LV) over time;
nevertheless, LV dimensions remained within normal
ranges of the physiological heart remodeling induced
by regular exercise. The authors concluded that the
presence of BAV does not represent an additional risk
for LV dilation and dysfunction, at least in the presence
of mild aortic valve dysfunction.2 Since in the presence
of moderate to severe or severe AR, athletes are usually
disqualified or discouraged from competitive sports
participation, no data are available to date on the pro-
gression of LV dilatation. Marfan syndrome (MFS), an
autosomal dominant connective tissue disorder exerted
by FBN-1 gene mutation, is another possible cause of
AR in young individuals. In MFS patients, the mech-
anism of AR is usually the result of aortic root dilation,
which develops and progresses gradually from an early
age, but at present no robust predictors of rapid aortic
root dilation exist, even if proximal aorta longitudinal
strain holds promise.3 In the 2017 European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery guidelines,3 indication for surgery in severe
chronic AR relies on the presence of symptoms and/
or aortic root dilation and/or LV dysfunction, as a
decline in LV ejection fraction 50% or LV enlarge-
ment identified by LV end-diastolic diameter>70mm or
LV end-systolic (LVESD) diameter >50mm. LVESD
should be indexed and a cut-off of 25mm/m2 seems
more appropriate in patients with small body surface
area (BSA) or in women.4 More recently, Yang et al.5
demonstrated that index LVESD is an important vari-
able to identify asymptomatic surgical candidates in the
presence of severe AR, because five-year survival started
to deteriorate when LVESD reached the cut-off value of
>20mm/m2. Independently of patient age, sex and small
BSA, referring to this newly proposed cut-off value will
favor early surgery for AR in a significant proportion of
patients. The best way to resolve this issue will be to
stratify patients based on index LVESD> 20mm/m2 in
a randomized controlled trial, being aware that patients
undergoing early surgery will be in better pre-operative
conditions than the control group – for now, the debate
remains.
In this issue of the journal, Antonopoulos et al.6
raised an important issue because the athlete’s heart is
characterized by LV dilation, which is more pro-
nounced in endurance athletes; therefore, in the pres-
ence of more than moderate AR, an accurate
distinction between physiological exercise-induced
remodeling and pathological LV dilation can be chal-
lenging. The authors commented on the pivotal role of
multi-modality imaging to correctly identify those ath-
letes who fall within the grey zone between those two
conditions. Transthoracic echocardiography is the
cornerstone of non-invasive imaging modalities to
follow-up athletes with BAV or AR in tricuspid aortic
valve, because it allows a detailed definition of
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aortic valve morphology and AR mechanism,
AR quantification, associated aortic dilation and hemo-
dynamic impact on LV. Reference values of LV dimen-
sion in athletes exist in adults7 and adolescents,8 and
both are very useful to outline an excessive LV dilation,
but more than the absolute value it is important to
highlight the temporal changes in LVESD and its
z-score growth velocity to determine the correct
timing for surgery.9 In addition to these parameters, a
newer echocardiographic marker is global longitudinal
strain (GLS), a measure of LV long-axis systolic func-
tion, which is more sensitive in identifying a dysfunc-
tion, even in the presence of normal LV ejection
fraction. GLS can predict the future need for surgery
and overall mortality in asymptomatic patients with
AR, and a worsening in LV GLS was significantly asso-
ciated with long-term mortality.10 Antonopoulos et al.6
highlighted the growing role of cardiac magnetic reson-
ance (CMR), which offers several advantages. First of
all, CMR allows a direct quantification of AR if echo-
cardiographic quantification of AR proves difficult, and
can reclassify AR severity in up to one third of the
cases. Moreover, CMR can further and deeper clarify
aortic valve morphology, properly discerning a BAV or
a tricuspid aortic valve, which has important prognos-
tic and therapeutic implications. CMR can identify the
exact mechanism of AR and the hemodynamic impact
on LV with the quantification of LV volumes and func-
tion and the aortic root dilation. An accurate diagnosis
with the quantification of these parameters is pivotal to
evaluate sports eligibility and in guiding decision-
making in top-level athletes. In contrast with echocar-
diography, CMR with the use of gadolinium allows
tissue characterization and, in particular, the identifica-
tion of fibrosis, which is a cause of sports ineligibility if
associated with major ventricular arrhythmias, leading
to cardiac sudden death. Antonopoulos et al.6 reported
that 10% of AR patients present interstitial fibrosis at
CMR independently of AR severity, and this could
potentially lead to exercise-induced arrhythmias.
Therefore, multimodality imaging studies are not
enough to identify those athletes who will benefit the
most from early surgery in the case of severe AR, but
a functional exam as stress test or exercise echocardio-
graphy is required to reveal symptoms and/or the pre-
sence of arrhythmias during effort. Maximal
cardiopulmonary exercise testing could also be promis-
ing in asymptomatic athletes with AR to evaluate exer-
cise tolerance, peak oxygen consumption and peak
exercise oxygen pulse,11 which holds promise as a pre-
dictor of cardiovascular mortality and could help in dif-
ferentiating athletes that fall within the grey zone
between physiological and pathological remodeling.
Last but not least, the recent insights of new molecu-
lar mechanisms underlying the development of AR,
mainly related to the presence of BAV, highlighted
the emerging critical role of phenotypic expression, cel-
lular and molecular mechanisms and pathways in deter-
mining the natural history and consecutive clinical
management of AR patients.12 Unveiling genetics, epi-
genetics and molecular pathways together with envir-
onmental factors will be a fundamental advance in
developing a personalized therapeutic approach.
Translational research provides major advances in the
scientific knowledge translating data from bench to
bedside, and hopefully it will provide new biomarkers
with diagnostic and prognostic implications also in AR.
We speculate to go beyond the valve morphology or
quantification as the only parameters for disqualifica-
tion from competitive sports participation or as recom-
mendation to surgical intervention. A modern strategy
would consider not only the clinical features but also
state-of-the-art imaging, molecular, cellular and genetic
profiles, particularly in athletes with AR.
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